Show newer

My latest clinical pipeline column for Nature Medicine is a look at a drug recently approved by the to delay the onset of type 1 diabetes.

It's a direct descendant of the very first monoclonal ever approved for clinical use.

nature.com/articles/d41591-022

Quick question for the Drosophila aficionados :) have ever come across with a suppressor of the dominant mutation IF? I have a IF/Cyo stock and everything is ok exempt that the IF eye ia gone :) i gave seen Tb disappear from a TM6b (where Hu is still around), but never had IF vanishing into oblivion… just curious….

I’m still not sure how this 🐘 works, but I guess the best is to start with an #introduction
Here I will be posting about stuff from our lab at the CECAD. We want to understand #aging and #proteostasis to prevent multiple age-related diseases such as #ALS, #Alzheimer, #Parkinson and #huntington

last boost (#LB?): LOVED Carolyn @bertozzi's answer when asked for whether her winning the Nobel Prize provides "an enhanced platform" to address gender issues in STEM (at time 22:00): "It's probably a question that's better posed to the men around the table...there are so many more of them and they are in a position to make change that's 9 times greater than my own position." 🙌🏽🙌🏽🙌🏽

RT @purveshkhatri
Excited to see our work advancing generalizability of host response-based diagnostics to address antimicrobial resistance for global population out today cell.com/cell-reports-medicine! Strong work from @adityarao95 who also developed a new analysis framework for this work!

One of the benefits of #Mastodon being #OpenSource: The EU can help make it more secure.

"Awards of up to EUR 5000 are available for finding security vulnerabilities in LibreOffice, LEOS, Mastodon, Odoo and CryptPad, open source solutions used by public services across the European Union. There is a 20% bonus for providing a code fix for the bugs they discover."
commission.europa.eu/news/euro

First post on mastodon! I'm thrilled to share our new manuscript on the metagenomic discovery, biochemistry, & structural insights of novel phage-derived CRISPR-Cas systems and their development into gene-editing tools! Now published @cellcellpress sciencedirect.com/science/arti

"The famed Copenhagen eatery, renowned as much for its culinary innovation as for its lively insect ingredients, has taken food condiments to new heights with its first microbe-made ‘garum’. Ancient Romans were said to go wild for this salty fish sauce and doused every possible meal with it, a bit like ketchup aficionados. Romans made garum by fermenting fish viscera in large, open vessels under the Mediterranean sun for up to three months. Many chefs have attempted to resurrect this so-called dodo of gastronomic history, with limited success — until now. Noma’s version, however, has no fish at all."

nature.com/articles/s41587-022

RT @deniz_cizmeci@twitter.com

Now available online! Pleased to present our human RSV challenge study. Thanks to the incredible participants, who make RSV vaccine development possible. @ragoninstitute@twitter.com @JanssenGlobal@twitter.com
authors.elsevier.com/c/1gElYL7

🐦🔗: twitter.com/deniz_cizmeci/stat

My latest clinical pipeline column for Nature Medicine is a look at a drug recently approved by the to delay the onset of type 1 diabetes.

It's a direct descendant of the very first monoclonal ever approved for clinical use.

nature.com/articles/d41591-022

'Why some animals can regenerate while many others cannot remains a fascinating question. Even amongst planarian flatworms, well-known for their ability to regenerate complete animals from small body fragments, species exist that have restricted regeneration abilities or are entirely regeneration incompetent. Towards the goal of probing the evolutionary dynamics of regeneration, we have assembled a diverse live collection of planarian species from around the world.'

biorxiv.org/content/10.1101/20

Final issue of our 40th #anniversary year!

Featured:
#LUBAC linear #ubiquitin signaling on #mitochondria
#Calnexin’s sugar-free taste in #lipid #bilayer
#Mitophagy receptors doubling in #pexophagy
#Cadherin-mediated #adhesion control (on the cover by Liang, Buckley et al)

...and more:
embopress.org/toc/14602075/202

@macroliter @alexcc yeah... there's a nihilism to publishing (and it's earned), but I asked if there were really differences amongst some of the publishers folks often discuss in the #PredatoryJournal discussion (e.g. Frontiers, MDPI). Held a poll, found out at least the rep is different. Then in analysis, found the same trend in terms of insular citations within network compared to expectation (via IF/SJR ratio).

#MDPI really is comparable to proper predatory publishers like Bentham or OMICs.

👏 👏 👏

"A life-size bronze statue of Henrietta Lacks, the woman whose cancer cells were taken without her consent and were used for research that ushered medical discoveries and treatments, will be erected in her hometown, Roanoke, Va., next year in a plaza previously named after the Confederate general Robert E. Lee."

nytimes.com/2022/12/20/us/henr

'It is a feature of America’s fragmented healthcare system that the private equity industry has seized upon. Over the past five years, some of the country’s biggest buyout firms have snapped up the companies that employ emergency room doctors, capturing some of the 18 per cent of gross domestic product that the US spends on medical care.'

ft.com/content/5673a288-f55b-4

Show older
CleverLibre Social

CleverLibre Social is an inclusive social instance for open discussion, learning, and community.
All cultures welcome.
Hate speech and harassment strictly forbidden.